The Patentability of Genetic Therapies: CAR-T and Medical Treatment Exclusions Around The World

59 Pages Posted: 7 Jun 2019 Last revised: 8 Aug 2019

See all articles by Luis Gil Abinader

Luis Gil Abinader

affiliation not provided to SSRN

Jorge L. Contreras

University of Utah - S.J. Quinney College of Law

Date Written: May 21, 2019

Abstract

More than eighty countries, including the members of the European Patent Convention, the United States, Canada, New Zealand, China, Japan, and India, currently exclude or limit the patentability of methods of medical treatment. CAR-T and other recent gene and cell therapies, which operate based on the extraction of genetic or cellular material from a patient, the alteration of such material, and the reintroduction of such material to the patient’s body, should, under most or all of these legal regimes, be considered medical treatments that are thus excluded from patentability, or as to which patent enforcement is limited. Accordingly, we urge national patent offices to update their examination procedures and practices to take these patentability limitations into account, and to publish guidance clearly explaining this approach to applicants.

Keywords: CAR-T, gene therapy, cell therapy, patent, medical treatment, European Patent Convention

Suggested Citation

Gil Abinader, Luis and Contreras, Jorge L., The Patentability of Genetic Therapies: CAR-T and Medical Treatment Exclusions Around The World (May 21, 2019). 34(4) American University International Law Review 705 (2019); University of Utah College of Law Research Paper No. 315. Available at SSRN: https://ssrn.com/abstract=3391788

Luis Gil Abinader

affiliation not provided to SSRN

Jorge L. Contreras (Contact Author)

University of Utah - S.J. Quinney College of Law ( email )

383 S. University Street
Salt Lake City, UT 84112-0730
United States

Register to save articles to
your library

Register

Paper statistics

Downloads
30
Abstract Views
121
PlumX Metrics